Benitec Biopharma Inc.
Financial highlights
| Metric | FY 06/30/25 | FY 06/30/24 | FY 06/30/23 | FY 06/30/22 | FY 06/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | $0 | $75,000 | $73,000 | $59,000 |
| Research and development | $18.3M | $15.6M | $12.8M | $11.3M | $7.0M |
| Operating expenses | $41.8M | $22.5M | $19.2M | $17.9M | $13.7M |
| Operating income | -$41.8M | -$22.5M | -$19.1M | -$17.9M | -$13.6M |
| Net income | -$37.9M | -$21.8M | -$19.6M | -$18.2M | -$13.9M |
| Balance Sheet | |||||
| Cash and equivalents | $97.7M | $50.9M | $2.5M | $4.1M | $19.8M |
| Current assets | $98.5M | $51.7M | $3.7M | $4.8M | $20.6M |
| Total assets | $99.6M | $52.2M | $4.5M | $6.0M | $21.4M |
| Current liabilities | $1.8M | $4.9M | $4.0M | $2.5M | $1.4M |
| Total liabilities | $2.3M | $5.0M | $4.3M | $3.1M | $1.4M |
| Stockholders' equity | $97.3M | $47.2M | $202,000 | $2.9M | $20.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$23.6M | -$19.4M | -$18.0M | -$15.9M | -$12.8M |
| Depreciation and amortization | $66,000 | $87,000 | $136,000 | $167,000 | $231,000 |
| Stock-based compensation | $17.4M | $830,000 | $452,000 | $870,000 | $634,000 |
| Capital expenditure | $18,000 | $179,000 | $1,000 | $13,000 | $221,000 |
| Free cash flow | -$23.6M | -$19.6M | -$18.0M | -$15.9M | -$13.1M |
Shares outstanding 34.4M · Free float 41.6%
Annual filing data through FY ended June 30, 2025; float as of July 15, 2026.